Skip to main content

Table 5 Model 2: Patient values vs. those of ethnic minorities (96 out of 908 are ethnic minorities)

From: Who should be prioritized for renal transplantation?: Analysis of key stakeholder preferences using discrete choice experiments

Variable

Coefficient for non-ethnic minorities

MRS for non-ethnic minorities

Coefficient for dummy variables for ethnic minorities

MRS for ethnic minority patients

Wald test p-values

Wait

.0451*

1

-.0061

1

 

Tiss

.0698*

1.54*

-.0630**

0.17

p<0.0001

  

(1.19 / 1.90)

 

(−0.82 / 1.17)

 

Dep

.0595*

1.32*

.0351*

2.42*

p=0.2755

  

(1.05 / 1.59)

 

(1.40 / 3.44)

 

Age

.0071*

0.16*

-.0011

0.15*

p=0.0024

  

(0.12 / 0.20)

 

(0.03 / 0.27)

 

dis1

.0039

0.09

-.0398

−0.92

p=0.6014

  

(−0.98 / 1.15)

 

(−4.41 / 2.57)

 

dis2

.7158*

15.86*

-.3153**

10.25*

p<0.0001

  

(13.87 / 17.85)

 

(4.96 / 15.53)

 

ill1

-.1085*

−2.40*

-.0903

−5.08*

p=0.9050

  

(−1.06 / -3.74)

 

(−0.83 / -9.33)

 

ill2

.1773*

3.93*

.0647

6.19*

p=0.2558

  

(2.82 / 5.03)

 

(2.51 / 9.88)

 

Intercepts

.1269*

 

-.0510

  

Variable

Non-ethnic minorities trade-off between variable & 1 year wait

Non-ethnic minorities trade-off between variable & 5 year wait

Ethnic minority trade-off between variable & 1 year wait

Ethnic minority trade-off between variable & 5 year wait

 

Prioritizing perfect not favourable tissue matches

1.54*

0.31*

0.17

0.35

 
 

(1.19 / 1.90)

(0.24 / 0.38)

(−0.82 / 1.17)

(−0.16/ 0.23)

 

Prioritizing favourable not non- favourable tissue matches.

4.64*

0.93*

0.52

0.10

 
 

(3.57 / 5.70)

(0.71 / 1.14)

(−2.46 / 3.50)

(−0.49 / 0.70)

 

Prioritizing a recipient with dependents per extra dependent

1.32*

0.26*

2.42**

0.48*

 
 

(1.05 / 1.59)

(0.21 / 0.32)

(1.40 / 3.44)

(0.28 / 0.69)

 

prioritizing a younger recipient per year younger

0.16*

0.03*

0.15*

0.03*

 
 

(0.12 / 0.20)

(0.02 / 0.04)

(0.03 / 0.27)

(0.01 / 0.05)

 

Prioritizing those with no not moderate diseases affecting life expectancy

0.09

0.02

−0.92

−0.18

 
 

(−0.98 / 1.15)

(−0.20 / 0.23)

(−4.41 / 2.57)

(−0.88 / 0.51)

 

Prioritizing those with moderate not severe diseases affecting life expectancy

15.86*

3.17*

10.25*

2.05*

 
 

(13.87 / 17.85)

(2.77 / 3.57)

(4.96 / 15.53)

(0.99 / 3.11)

 

Prioritizing those with no not moderate diseases affecting QoL

−2.40*

−0.48*

−5.08*

−1.02*

 
 

(−1.06 / -3.74)

(−0.21 / -0.75)

(−0.83 / -9.33)

(−0.17 / -1.87)

 

Prioritizing those with moderate not severe diseases affecting QoL

3.93*

0.79*

6.19*

1.24*

 
 

(2.82 / 5.03)

(0.56 / 1.01)

(2.51 / 9.88)

(0.50 / 1.98)

 
  1. *: Significant at the 5% level; Figures in parentheses indicate 95% confidence intervals for point estimates.
  2. Includes MRS expressed in terms of utility value of other attributes expressed in terms of trade-off with 1 year and 5 year waiting time.